MINC‑trastuzumab
HER2‑positive breast cancer
PreclinicalActive
Key Facts
About Suntec Medical
SunTec uses EGCG‑based nanocomplexes to deliver multi‑target immunotherapies for hard‑to‑treat cancers and CNS diseases.
View full company profileTherapeutic Areas
Other HER2‑positive breast cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Herceptin (Trastuzumab) Biosimilar | NeuClone | Phase 1 |
| Perjeta (Pertuzumab) Biosimilar | NeuClone | Process Scale‑up |
| MagSense™ HER2 Imaging Agent | Imagion Biosystems | Phase 2 |
| P-003 | Panacea Biotec | Phase 3 |
| Trastuzumab Biosimilar | Hetero | Phase 3 |
| Legrand‑Herceptin Biosimilar | Laboratorios Legrand | Commercial |
| AfriMab-1 | Afrigen Biologics | Preclinical |
| Biosimilar Trastuzumab | Biosidus | Commercial |
| Trazher | Innogene Kalbiotech | Commercial |